We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Ssl Intl. | LSE:SSL | London | Ordinary Share | GB0007981128 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1,163.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
25/11/2009 08:24 | Broker recommendation full details Date: 25 November, 2009 Broker: Deutsche Bank Company: SSL Recommendation: Raises price target to 800p from 750 | enami | |
24/11/2009 14:51 | WOW really surging ahead after US open. Results look good. Hit target as per post 1313 (726) - next target 800 | enami | |
23/11/2009 11:06 | INSIDE LEG: Will Reckitt Benckiser go for SSL? 23 November, 2009 08:57:56 AM EVolution reckons it makes a good bite-sized opportunity. Says the other rumoured play, Colgate, just too big and there would be issues of management control. Here the broker assess the rationale behind both deals: 'Last week's share price rally in reaction to press speculation that multi-billion dollar M&A activity was imminent reflects the markets desire for RB to make an acquisition. We believe that Colgate-Palmolive, a suggested name, would be too large to acquire and as a merger partner would involve issues of management control. However, SSL would be a fraction of its size and would yield excellent cost saving and cash flow opportunities. If M&A speculation falls away the market will revert to focusing on the existing businesses and it is worth taking full note of the advent of a potentially more effect rival to Suboxone called Vivitrol whose parent Alkermes has reported positive results from Phase 3 clinical studies. This is new news and suggests that the worst case scenarios baked in to FY10 forecasts could be reality. This is in addition to the challenge posed by P&G and others to 3 out of 4 RB household divisions.' | enami | |
20/11/2009 10:03 | Broker recommendation full details Date: 21 November, 2009 Broker: Deutsche Bank Company: SSL International Recommendation: Retain Buy price price target raised to 750p from 575p | enami | |
20/11/2009 07:52 | Reckitt May Be Close To Merger With Colgate Speculation that Reckitt Benckiser may merge with US peer Colgate-Palmolive could be bad news for Durex condom firm SSL International. The bid premium of SSL is likely to disappear if Reckitt bids for anyone else, making SSL a 'sell' in the eyes of finnCap. | enami | |
19/11/2009 12:52 | Thanks, doing well today in the runup to results next Tuesday, maybe will crack 700 before then. | enami | |
14/11/2009 11:56 | Enami- the company announced the date here: | sharw | |
13/11/2009 10:41 | Does anybody know when the Interim Results are due? Historically in the last 2 weeks of November but the SSL website has no info and no contact email addresses. Performing quite well so far this month and as I type the share price is matching the highest EOD close (652). | enami | |
22/10/2009 13:25 | Only stock in my portfolio showing a gain today and thats only a fiver LOL | volsung | |
20/10/2009 12:37 | Good news for us! | volsung | |
16/10/2009 16:02 | Very good trading statement too :) | volsung | |
16/10/2009 15:17 | I totally missed the fact that there was a trading statement on Tuesday, it must be OK otherwise the share price would have plummeted. | enami | |
16/10/2009 15:11 | Bought a few more on the dip | volsung | |
11/10/2009 22:34 | From intermarketstocks.co BROKER CALL:Broker talks up SSL potential 9 October, 2009 11:49:53 AM Shares in the consumer brand company are 4p higher at 635p, in what is a pretty quiet market, helped by Nomura reiterating a Buy stance and 690p price target. The broker believes the market continues to underestimate the Chinese opportunity, medium term prospects in Russia and an increased take-out opportunity. It added that it has a 900p take-out value. We've also heard that the company may be about to reveal a blockbuster of a product, though further info was not forthcoming. And from FUM results afew weeks ago "SSL is well advanced with the branding, marketing and launch plans for the condom, which will be marketed within the Durex range of products." :@)) | captain_kurt | |
09/10/2009 13:41 | Broker recommendation full details Date: 9 October, 2009 Broker: Nomura Company: SSL International Recommendation: Raises price target to 690p from 580 EDIT I assume the huge spike yesterday was the Nomura clients buying in. | enami | |
02/10/2009 11:18 | reckitt to beat the americans- see IC pg 64. also see FUM p 62 | mr bean2 | |
30/9/2009 17:07 | Nice spike at the end there :) | volsung | |
29/9/2009 14:45 | Recounted wave target now 726 | enami | |
29/9/2009 14:34 | Edited due upside target recount. | enami | |
29/9/2009 14:26 | Almost at my target (640). More than 100p swing from this month's low 536. Profit slicing order set for 639. | enami | |
24/9/2009 07:51 | Futura nears product launch GrowthBusiness.co.uk - 23rd Sept 2009 This would pave the way for the launch of the product with Futura's partner, Durex maker SSL International, as a 'Durex-branded condom'. ... | captain_kurt | |
23/9/2009 09:26 | back in the game again with these | volsung | |
22/9/2009 08:40 | Big boys are singled out as bid targets | lbo | |
10/9/2009 16:27 | 08 September 2009 "Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, is pleased to announce that CSD500, its lead product to be launched as a Durex -branded condom by SSL International plc (SSL), is on track to receive the CE Mark following the transfer of manufacturing by SSL to facilities in India." Money maker for SSL ! | captain_kurt |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions